In the mid-1990s, Hiroyuki Nakai, now an adeno-associated virus (AAV) researcher at the Oregon Health and Science University, moved to the United States. Nakai quickly became fascinated with the ...
Poster #122: Development of alternatives to Triton X-100 cell lysis for AAV2, AAV5 and AAV8 primary recovery Category: AAV & non integrative vectors Triton X-100 is an effective detergent for ...
Researchers from MIT have developed a bioreactor simulator to predict adeno-associated virus (AAV) yields for insect cell/baculovirus manufacturing. Francesco Destro, PhD, a postdoctoral associate ...
A study published last week presents a compact base editor that enables efficient in vivo delivery using a single adeno-associated virus (AAV) vector. The innovation, once approved in clinical trials, ...
What Are AAV Vector-Based Therapies? Gene therapies are groundbreaking approaches utilizing viral and non-viral vectors. These vectors introduce therapeutic genes into patient cells to treat diseases, ...
CNS-directed AAV gene therapy shows milder immune responses compared to systemic administration, reducing peripheral immune activation and systemic toxicities. Direct CNS delivery can bypass ...
HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback